Our analysis contributes to a growing literature emphasizing gender differences in the MPN, which already includes differences in the JAK2 V617F allele burden and disease class and further supports the important impact of individual and host variation on the clinical manifestations of the MPN [27]. Here, JAK2 is linked to myeloproliferative neoplasm.